American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Kyverna Therapeutics, Inc. (KYTX)

$5.39 -5.93% NASDAQ: KYTX · 15-min delayed

EMERYVILLE, California
Public · NASDAQ: KYTX
129 employees

Visit website Follow

$450.5MMarket cap

-$161.3MNet income

129Employees

KYTXNASDAQ

2024IPO

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: KYTX
Employees: 129
IPO date: Feb 8, 2024
Headquarters: 5980 HORTON STREET
EMERYVILLE, California 94608
Phone: (510) 626-8331
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: KYTX Nasdaq
SEC CIK: 1994702
LEI: 549300I1AHR8KMMFIS52
EIN: 831365441
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Kyverna Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/kyverna-therapeutics-inc/"><img src="https://americancompanies.com/badge/kyverna-therapeutics-inc.svg" alt="Kyverna Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Kyverna Therapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: -$161.3M
Total assets: $293.8M
Market cap: $450.5M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: KYTX

$5.39 -5.93%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$5.39 $11.25

52-week range

Market cap: $450.5M
Shares outstanding: 83.6M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Feb 8, 2024

Kyverna Therapeutics, Inc. (KYTX) Stock Price

Reported a net loss of $161.3M.
Trading 52% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Kyverna Therapeutics, Inc..

Write a review

Newsroom

News about Kyverna Therapeutics, Inc.

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight GlobeNewswire Inc. · 2026-06-10 · positive Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? The Motley Fool · 2026-06-08 · negative Kyverna Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc. · 2026-05-14 · positive Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting GlobeNewswire Inc. · 2026-04-21 · positive Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors GlobeNewswire Inc. · 2026-02-24 · positive How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? Benzinga · 2025-12-31 · positive

News & sentiment via Polygon.io

FAQ

Kyverna Therapeutics, Inc.: frequently asked questions

Is Kyverna Therapeutics, Inc. an American company?

Kyverna Therapeutics, Inc. is a US-based company headquartered in Emeryville, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Kyverna Therapeutics, Inc. headquartered?

Kyverna Therapeutics, Inc. is headquartered in Emeryville, California, United States.

Is Kyverna Therapeutics, Inc. publicly traded?

Yes — Kyverna Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol KYTX on the NASDAQ.

What does Kyverna Therapeutics, Inc. do?

Kyverna Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore